A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis
A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis
复制标题
DOI：
10.1002/art.1780390413
复制
发表时间：
1996-04-01
影响因子：
--
通讯作者：
Trentham, DE
中科院分区：
文献类型：
--
作者：
Barnett, ML;Combitchi, D;Trentham, DE
Objective.评价口服鸡II型胶原蛋白（CCII）治疗幼年型类风湿关节炎（JRA）的疗效。10例活动性JRA患者接受CCII治疗12周，每月评估疗效指标，包括肿胀和压痛关节计数和评分、握力、50英尺步行时间、晨僵持续时间以及患者和医生的疾病严重程度总体评分。所有患者均完成了整个疗程，8例患者在CCII治疗3个月后肿胀和压痛关节计数均减少。研究结束时，8例应答者肿胀和压痛关节计数较基线的平均变化分别为-61%和-54%。其他疗效参数的平均值也显示较基线改善。未发现与治疗相关的不良事件。口服CCII可能是一种安全有效的治疗JRA的方法，其在这种疾病中的应用值得进一步研究。
Objective. To evaluate the efficacy of oral chicken type II collagen (CCII) in the treatment of juvenile rheumatoid arthritis (JRA).Methods. Ten patients with active JRA were treated with CCII for 12 weeks, Efficacy parameters, which included swollen and tender joint count and score, grip strength, 50-foot walking time, duration of morning stiffness, and patient and physician global scores of disease severity, were assessed monthly.Results. All patients completed the full course of therapy, Eight patients had reductions in both swollen and tender joint counts after 3 months of CCII. The mean changes from baseline in swollen and tender joint counts for the 8 responders at the end of the study were -61% and -54%, respectively. Mean values for other efficacy parameters also showed improvement from baseline. There were no adverse events that were considered to be treatment related.Conclusion. Oral CCII may be a safe and effective therapy for JRA, and its use in this disease warrants further investigation.